Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Fresenius Medical Care AG & Co. KGaA (FMEN) AI Stock Analysis

MX:FMEN

Fresenius Medical Care AG & Co. KGaA

(BMV:FMEN)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring Integrated Business ModelFrequent dialysis treatments and recurring consumables create a durable revenue base tied to patient volumes and treatment counts. FME’s combination of care delivery and product supply also links two complementary businesses, supporting customer continuity and operational scale over multiple quarters.
Negative Factors
Modest Net ProfitabilityDespite stronger operating results, only a modest share of revenue reaches the bottom line, and net margin remains below the prior 2025 level. This limits earnings conversion and leaves profitability sensitive to costs below operating income, including interest, taxes, and other items.

Fresenius Medical Care AG & Co. KGaA (FMEN) vs. SPDR S&P 500 ETF (SPY)

-15%-10%-5%0%5%10%15%20%MX:FMEN-5.06%SPY+8.82%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
MXN 232.58B
Dividend Yield
3.84%
Average Volume (3M)
―
Price to Earnings (P/E)
14.1
Beta (1Y)
0.01
Revenue Growth
-6.36%
EPS Growth
15.38%
Country
Mexico
Employees
107,226
Sector
General
Sector Strength
55
Industry
Medical - Care Facilities

Fresenius Medical Care AG & Co. KGaA Business Overview & Revenue Model

Company Description

Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential...

Fresenius Medical Care AG & Co. KGaA Risk Analysis

Fresenius Medical Care AG & Co. KGaA disclosed 26 risk factors in its most recent earnings report. Fresenius Medical Care AG & Co. KGaA reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

2 New Risks
1.We need to develop new internal functions to perform certain business services that Fresenius SE provided to us prior to the Conversion.Q4, 2023
2.As a company with operations spanning 150 countries, we face specific risks from our global operations.Q4, 2023

Fresenius Medical Care AG & Co. KGaA Peers Comparison

Overall Rating

Financial Indicators

MX:FMEN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

-10%-5%0%MX:FMENDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
MX:FMEN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MX:FMENFresenius Medical Care AG & Co. KGaA822.02-43.80-5.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.